Previous 10 | Next 10 |
Urovant Sciences (Nasdaq: UROV) announced today that it will report 2019 third fiscal quarter financial results after the close of U.S. financial markets on Thursday, February 13, 2020. Management will host a conference call to discuss Urovant’s financial results at 1:30 p.m. Pac...
Urovant Sciences (NASDAQ: UROV ) announces the publication, online in Neurology and Urodynamics , of results from two Phase 1 clinical trials evaluating gene therapy URO-902 in female patients with overactive bladder. More news on: Urovant Sciences Ltd., Healthcare stocks news, Read...
Urovant Sciences (Nasdaq: UROV) announced today the publication of the safety and efficacy results of URO-902 in female patients with overactive bladder (OAB) from two double-blind, placebo-controlled randomized Phase 1 trials. The first trial was conducted with instillation therapy and the...
This article was highlighted for PRO+ subscribers, Seeking Alpha’s service for professional investors. Find out how you can get the best content on Seeking Alpha here . Urovant Sciences (UROV) is a hidden gem—a significantly undervalued company that has been significantly de...
Urovant Sciences (Nasdaq: UROV) announced today that Chief Executive Officer Keith Katkin and other Urovant executives will ring the opening bell of the Nasdaq Stock Market on Tuesday, January 21, 2020, at 9:30 a.m. Eastern. The ceremony will begin at 9:20 a.m. To view a live stream of ...
Urovant Sciences (Nasdaq: UROV) announced today that Chief Executive Officer Keith Katkin will give a presentation at 4:30 p.m. Pacific / 7:30 p.m. Eastern on Wednesday, January 15, 2020, at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco. A live, audio webcast for th...
Urovant Sciences (Nasdaq: UROV) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of once-daily 75mg vibegron for the treatment of patients with overactive bladder (OAB) with symptoms of urge urinary incontinen...
Urovant Sciences (NASDAQ: UROV ) has entered into a $300M term loan facility with Sumitomo Dainippon Pharma Co., Ltd. More news on: Urovant Sciences Ltd., Healthcare stocks news, Read more ...
Urovant Sciences (Nasdaq: UROV) (“Urovant”) announced today that it has entered into a $300 million term loan facility with Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506) (“Sumitomo Dainippon Pharma”), a leading global Japanese pharmaceutical company. Urovant pl...
Urovant Sciences (Nasdaq: UROV) (“Urovant”) announced today that its majority shareholder, Roivant Sciences Ltd. (“Roivant”), and Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506) (“Sumitomo Dainippon Pharma”), a leading global Japanese pharmaceutical...
News, Short Squeeze, Breakout and More Instantly...
Urovant Sciences Ltd. Company Name:
UROV Stock Symbol:
NASDAQ Market:
Urovant Sciences Ltd. Website:
Interim 12-week analysis from a Phase 2a trial of the potential gene therapy, URO-902, in women with overactive bladder (OAB) and urge urinary incontinence (UUI) will be featured in a late breaker presentation by Kenneth M. Peters, M.D. during Friday morning’s plenary session...
Study showed clinically meaningful impact on common symptoms of overactive bladder (OAB) compared to placebo from baseline to week 12 Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced positive topline results from its Phase 2a, double-...
Data from the 12-week EMPOWUR trial regarding patient perceptions of improvement of OAB symptoms show that significantly more patients treated once-daily with GEMTESA ® (vibegron) experienced patient-perceived improvements due to the reduction in micturition frequency (urin...